Invitrogen Corp. announced it has entered a research collaboration with Novartis Institute for Functional Genomics to further the study of genes.
The announcement was made Dec. 16.
Under the agreement, the San Diego-based Institute will get access to Invitrogen’s cloning technologies and expression systems.
Invitrogen, based in San Diego, receives the rights to sell clones and reagents developed by Novartis.
The collaboration will allow Novartis to set up a high-throughput cloning facility using Invitrogen’s latest technology, which was introduced mid-December.
“The Novartis Institute for Functional Genomics will be able to significantly expand its cloning activities thanks to the improved capabilities of our new echo system,” said Lyle Turner, chairman and CEO of Invitrogen.